Financials data is unavailable for this security.
View more
Year on year ZYUS Life Sciences Corp had net income fall 72.73% from a loss of 24.66m to a larger loss of 42.59m despite a 17.79% increase in revenues from 298.00k to 351.00k. An increase in the selling, general and administrative costs as a percentage of sales from 3,169.46% to 3,588.60% was a component in the falling net income despite rising revenues.
| Gross margin | 46.50% |
|---|---|
| Net profit margin | -8,604.67% |
| Operating margin | -9,752.57% |
| Return on assets | -63.34% |
|---|---|
| Return on equity | -110.77% |
| Return on investment | -88.37% |
More ▼
Cash flow in CADView more
In 2023, ZYUS Life Sciences Corp increased its cash reserves by 1,776.42%, or 3.77m. Cash Flow from Financing totalled 17.14m or 4,882.62% of revenues. In addition the company used 18.01m for operations while cash from investing totalled 4.64m.
| Cash flow per share | -0.4803 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.2192 |
|---|---|
| Tangible book value per share | -0.0432 |
More ▼
Balance sheet in CADView more
| Current ratio | 0.2952 |
|---|---|
| Quick ratio | 0.1593 |
| Total debt/total equity | 0.6542 |
|---|---|
| Total debt/total capital | 0.3955 |
More ▼
Growth rates in CAD
SmartText is unavailable
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -3.09 |
